Gene-Targeted Tauopathy Models for Accelerated Tau Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models for tauopathies, such as Alzheimer's disease and frontotemporal dementia, lack effective methods to study and intervene in the abnormal protein aggregation and propagation that cause neurotoxicity, which are key features of these diseases.
Innovation Solution
Development of non-human animal models with genetic modifications in BANF1, PPP2CA, and ANKLE2 to reduce their expression, combined with exogenous human microtubule-associated protein tau coding sequences, to create improved tauopathy models that enhance tau aggregation and propagation for therapeutic assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic modifications are introduced to reduce expression of BANF1, PPP2CA, and ANKLE2, then tau aggregation and propagation are enhanced for better disease modeling, but model complexity and manufacturing difficulty increase
Solution Approach 1:
The patent divides the complex genetic modification process into separate, manageable components by targeting individual genes (BANF1, PPP2CA, ANKLE2) independently. Each gene modification can be developed, validated, and implemented separately, allowing for systematic optimization and reducing overall complexity while achieving enhanced tau aggregation and propagation in the model system.
2Reliability
If exogenous human tau coding sequences are introduced, then tauopathy progression is better represented, but risk of immune response and model instability increases
Solution Approach 1:
The patent applies local quality by selectively introducing exogenous human tau coding sequences only in specific regions or cell types where tau pathology is most relevant, rather than uniformly throughout the entire organism. This localized approach maintains high fidelity in representing tauopathy progression while minimizing systemic immune responses and model instability.
3Productivity
If multiple gene expressions are reduced to enhance tau aggregation, then therapeutic screening effectiveness is improved, but time and resources required for model development increase
Solution Approach 1:
The patent implements preliminary action by pre-validating and optimizing the genetic modification protocols for BANF1, PPP2CA, and ANKLE2 before full-scale therapeutic screening. By establishing standardized, pre-tested modification procedures and pre-characterizing the resulting tau aggregation phenotypes, the model development time is reduced while maintaining high therapeutic screening effectiveness.
Data Source
AI summary
BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.